Photo of Prof William Hope

Prof William Hope FRACP, FRCPA, PhD

Dame Sally Davies Chair of AMR Research, Director of Centre of Excellence in Infectious Diseases Research Molecular and Clinical Pharmacology

Research

Research Interest 1

The research themes of the Antimicrobial Pharmacodynamics and Therapeutics Laboratory are as follows:

1. Development of New Antimicrobial Agents
2. Repurposing and Optimisation
3. Antimicrobials for Neonates and Children
4. Antimicrobials for Neglected Tropical Diseases
5. Individualisation of Antimicrobial Therapy


Details of each research theme can be found at Antimicrobial Pharmacodynamics and Therapeutics

Research Grants

ANT3310 - Assessment of the pharmacodynamics of ANT3310 a serine beta-lactamase inhibitor

ANTABIO (FRANCE)

January 2020 - July 2020

Pharmacodynamics of Amphotericin B Cochleates for Cryptococcal Meningitis

MATINAS BIOPHARMA NANOTECHNOLOGIES, INC (USA)

April 2017 - July 2017

Pharmacodynamics of Tebipenem

SPERO OPCO INC (USA)

August 2016 - July 2018

High Dose AMBISOME© on a Fluconazole Backbone for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: A Randomized Controlled Non-inferiority Trial (AMBITION)

EDCTP (NETHERLANDS)

January 2017 - December 2020

Pharamcodyanmics of new antimicrobial agents for neonatal meningitis

FOOD AND DRUG ADMINISTATION (USA)

September 2016 - September 2019

Assessment of tebipenem in the hollow fibre

SPERO OPCO INC (USA)

August 2016 - July 2018

ADAPT

DEPARTMENT OF HEALTH (UK) (NIHR)

April 2019 - March 2021

Pharmacodynamics of SPR206

SPERO OPCO INC (USA)

June 2018 - July 2020

Pharmacodynamics of Meropenem and metallobetalactmase inhibitors against NDM producing Gram Negatives

ANTABIO (FRANCE)

September 2017 - February 2018

Pharmacodynamics of Antimicrobial Combinations for Neonatal Sepsis in Low-To-Middle Income Countries

DRUGS FOR NEGLECTED DISEASES INITIATIVE (DNDI) (SWITZERLAND)

November 2018 - November 2019

AAI101 and Cefepime in Epithelial Lining Fluid and Plasma in Healthy Volunteers REC

ALLECRA THERAPEUTICS GMBH (GERMANY)

January 2018 - September 2022

PK-PD analyses of cefepime and AAI101 against MDR enterobacteriaceae

ALLECRA THERAPEUTICS GMBH (GERMANY)

October 2017 - October 2018

Unlocking the potential of teixobactin analogues to target multi-drug resistant bacteria (TBC)

INNOVATE UK (UK)

April 2019 - September 2020

Pharmacokinetic-Pharmacodynamic analyses of novel metallo-betalactmase inhibitors in multidrug resistant Gram negative infections

ANTABIO (FRANCE)

May 2018 - October 2019

Assessment of the PKPD of BWC0977

BUGWORKS RESEARCH INDIA PVT. LTD. (INDIA)

May 2019 - May 2021

Spatially-resolved PKPD modelling for optimised treatment of central nervous system infection due to Mycobacterium tuberculosis

MEDICAL RESEARCH COUNCIL (MRC)

August 2016 - July 2019

Rational Design, Synthesis and Biological Evaluation of Benzimidazoles Towards a Novel Therapy Selectively Targeting C. neoformans beta-tubulin

MEDICAL RESEARCH COUNCIL (MRC)

July 2016 - December 2019

Centre for Antimicrobial Pharmacodynamics

INNOVATE UK (UK)

January 2017 - March 2017

Pharmacodynamics of Novel Potentiators Against Multidrug Resistant Gram Negative Infections

SPERO OPCO INC (USA)

August 2016 - July 2017

Combatting Bacterial Resistance in Europe COMBACTE-MAGNET

AICURIS GMBH (GERMANY), EUROPEAN COMMISSION

January 2015 - December 2021

Pharmacodynamics of Novel Antifungal Agents Against Aspergillus fumigatus

F2G LTD (UK)

May 2013 - June 2016

Pharmacodynamics of Voricamozole against fusarium SPP and scedosporium apiospermum: Identification of in vitro suscepibility breakpoints and targets for theraputic drug monitoring

EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES (SWITZERLAND)

June 2013 - May 2014

Preserving old antibiotics for the future : assessment of clinical efficacy by a pharmacokinetic/pharmacodynamic approach to optimize effectiveness and reduce resistance for off‐patent antibiotics

EUROPEAN COMMISSION

April 2013 - November 2016

Towards complete sustained release nanoformulations of NRTI based regimens

NATIONAL INSTITUTES OF HEALTH (NIH) (USA)

July 2014 - June 2019

Generating Micafungin amd Isavuconazole MICs Versus Candida spp. using EUCAST Methodology

ASTELLAS PHARMA GLOBAL DEVELOPMENT (USA)

August 2012 - July 2013

A Control Theory Approach for Individualisation of Antifungal dosing in Immunocomprised Patients

DEPARTMENT OF HEALTH (UK) (NIHR)

June 2012 - September 2016

Treatment of late onset bacterial sepsis caused by Vancomycin susceptible bacteria in neonates and infants aged under three months (NeoVanc)

EUROPEAN COMMISSION

February 2014 - July 2020

Cryptococcal meningitis: addressing an urgent global health problem using a translational pharmacological approach

MEDICAL RESEARCH COUNCIL (MRC)

December 2012 - February 2015